Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Exclusion Criteria

• •1. Systolic blood pressure \>130 mm Hg or diastolic blood pressure \>80 mm Hg.
• •2. Presence of any secondary IgAN.
• •3. Presence of rapidly progressive glomerulonephritis.
• •4. Presence of other chronic kidney diseases.
• •5. Patients with a diagnosis of type 1 or type 2 diabetes mellitus.
• •6. A history of invasive infections caused by encapsulated bacteria, e.g., meningococci or pneumococci.
• •7. Patients previously treated with immunosuppressive agents exposure within 90 days prior to start of study drug dosing.
• •8. Patients previously treated with traditional Chinese medicine containing immunosuppressive ingredients within 90 days prior to start of study drug dosing.
• •9. Patients who had been treated with any systemic corticosteroids within the 180 days before treatment ≥20 mg/d for primary IgAN indication.
• •10. Patients who previously have received biologic agent or monoclonal antibodies prior to start of study drug dosing within 5 half-lives or 30 days (whichever is longer).
• •11. Patients who have received live/attenuated vaccines within the 4 weeks prior to randomization, or plan to receive during the trial.